参考文献/References:
[1] Roth GA,Mensah GA,Johnson CO,et al. Global burden of cardiovascular diseases and risk factors,1990—2019:update from the GBD 2019 study[J]. J Am Coll Cardiol,2020,76(25):2982-3021.
[2] GBD 2017 Causes of Death Collaborators. Global,regional,and national age-sex-specific mortality for 282 causes of death in 195 countries and territories,1980—2017:a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet,2018,392(10159):1736-1788.
[3] Bannehr M,Edlinger CR,Kahn U,et al. Natural course of tricuspid regurgitation and prognostic implications[J]. Open Heart,2021,8(1):e001529.
[4] Patlolla SH,Schaff HV,Nishimura RA,et al. Incidence and burden of tricuspid regurgitation in patients with atrial fibrillation[J]. J Am Coll Cardiol,2022,80(24):2289-2298.
[5] Kubala M,de Chillou C,Bohbot Y,et al. Arrhythmias in patients with valvular heart disease:gaps in knowledge and the way forward[J]. Front Cardiovasc Med,2022,9:792559.
[6] Miyasaka Y,Barnes ME,Gersh BJ,et al. Secular trends in incidence of atrial fibrillation in Olmsted County,Minnesota,1980 to 2000,and implications on the projections for future prevalence[J]. Circulation,2006,114(2):119-125.
[7] 王刚,冯天元. 功能性三尖瓣反流的临床研究进展[J] .中国心血管杂志,2017,22(6):460-463.
[8] 赵晓妮,胥盼,刘艳,等. 三维超声心动图评估功能性三尖瓣反流患者形态结构改变机制[J] . 中华超声影像学杂志,2021,30(12):1033-1038.
[9] Patlolla SH,Kandlakunta S,Boyapalli S,et al. Prevalence of tricuspid and mitral valve regurgitation in patients with non-paroxysmal atrial fibrillation in the United States[J]. J Am Coll Cardiol,2023,81(suppl 8 ):1964.
[10] McCarthy PM,Szlapka M,Kruse J,et al. The relationship of atrial fibrillation and tricuspid annular dilation to late tricuspid regurgitation in patients with degenerative mitral repair[J]. J Thorac Cardiovasc Surg,2021,161(6):2030-2040.
[11] Kim YS,Jeong HG,Hwang IC,et al. Tricuspid regurgitation:a hidden risk factor for atrial fibrillation related stroke?[J]. Front Cardiovasc Med,202310:1135069.
[12] Cho MS,Cha MJ,Nam GB,et al. Incidence and predictors of severe tricuspid regurgitation in atrial fibrillation patients without structural heart disease[J]. Am J Cardiol,2023,203:288-294.
[13] Ricci F,Bufano G,Galusko V,et al. Tricuspid regurgitation management:a systematic review of clinical practice guidelines and recommendations[J]. Eur Heart J Qual Care Clin Outcomes,2022,8(3):238-248.
[14] Fortuni F,Dietz MF,Prihadi EA,et al. The truly forgotten chamber:prognostic value of right atrial dilation in patients with sinus rhythm and significant functional tricuspid regurgitation[J],Eur Heart J,2020,41(suppl 2):1887.
[15] Tomaselli M,Radu DN,Badano LP,et al. Right atrial remodeling and outcome in patients with secondary tricuspid regurgitation[J]. J Am Soc Echocardiogr,2024,37(5):495-505.
[16] Yoshida K,Wezenbeek JV,Wessels JN,et al. Tricuspid regurgitation in pulmonary arterial hypertension:relations with right ventricular function and prognosis[J]. Eur Heart J,2023,44(suppl 2):ehad655.2000.
[17] Galloo X,Fortuni F,Meucci MC,et al. Association of right atrial strain and long-term outcome in severe secondary tricuspid regurgitation[J]. Heart,2024,110(6):448-456.
[18] Pype L,Embrechts L,Cornez B,et al. Long-term effect of atrial fibrillation on the evolution of mitral and tricuspid valve regurgitation[J]. Acta Cardiol,2020,75(7):639-647.
[19] Utsunomiya H,Harada Y,Susawa H,et al. Abstract 15424:tricuspid valve geometry and right heart remodeling:insights into the mechanism of atrial functional tricuspid regurgitation[J]. Circulation,2020,142(suppl 3):A15424.
[20] Margonato D,Ancona F,Ingallina G,et al. Tricuspid regurgitation in left ventricular systolic dysfunction:marker or target?[J]. Front Cardiovasc Med,2021,8:702589.
[21] Muraru D,Badano LP,Hahn RT,et al. Atrial secondary tricuspid regurgitation:pathophysiology,definition,diagnosis,and treatment[J]. Eur Heart J,2024,45(11):895-911.
[22] Ortiz-Leon XA,Posada-Martinez EL,Trejo-Paredes MC,et al. Tricuspid and mitral remodelling in atrial fibrillation:a three-dimensional echocardiographic study[J]. Eur Heart J Cardiovasc Imaging,2022,23(7):944-955.
[23] Ortiz-Leon XA,Posada-Martinez EL,Trejo-Paredes MC,et al. Understanding tricuspid valve remodelling in atrial fibrillation using three-dimensional echocardiography[J]. Eur Heart J Cardiovasc Imaging,2020,21(7):747-755.
[24] Nattel S,Burstein B,Dobrev D. Atrial remodeling and atrial fibrillation:mechanisms and implication[J]. Circ Arrhythm Electrophysiol,2008,1(1):62-73.
[25] Allessie M,Ausma J,Schotten U. Electrical,contractile and structural remodeling during atrial fibrillation[J]. Cardiovasc Res,2002,54(2):230-246.
[26] Schotten U,Verheule S,Kirchhof P,et al. Pathophysiological mechanisms of atrial fibrillation:a translational appraisal[J]. Physiol Rev,2011,91(1):265-325.
[27] Vandenberk B,Haemers P,Morillo C. The autonomic nervous system in atrial fibrillation-pathophysiology and non-invasive assessment[J]. Front Cardiovasc Med,2024,10:1327387.
[28] Surapaneni P,Vinales KL,Najib MQ,et al. Valvular heart disease with the use of fenfluramine-phentermine[J]. Tex Heart Inst J,2011,38(5):581-583.
[29] Peraza-Zaldivar JA,Ponce-Guarneros JM,Cardona-Mu?oz EG,et al. Effects of renin-angiotensin system inhibitors on atrial mechanics parameters in patients with metabolic syndrome[J]. J Cardiovasc Pharmacol Ther,2023,28:10742484231216807.
[30] Martin AC,Bories MC,Tence N,et al. Epidemiology,pathophysiology,and management of native atrioventricular valve regurgitation in heart failure patients[J]. Front Cardiovasc Med,2021,8:713658.
[31] Büttner P,Schumacher K,Dinov B,et al. Role of NT-proANP and NT-proBNP in patients with atrial fibrillation:association with atrial fibrillation progression phenotypes[J]. Heart Rhythm,2018,15(8):1132-1137.
[32] Li JY,Liang GC,Huang FL,et al. The Correlation of inflammation,oxidative stress,and hippocampal perfusion in patients with atrial fibrillation[J]. Int Heart J,2023,64(6):1018-1024.
[33] Kitamura M,Fam NP,Braun D,Ruf T,et al. 12-month outcomes of transcatheter tricuspid valve repair with the PASCAL system for severe tricuspid regurgitation[J]. Catheter Cardiovasc Interv,2021,97(6):1281-1289.
[34] Vahanian A,Beyersdorf F,Praz F,et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease[J]. Eur Heart J,2022,43(7):561-632.
[35] National Guideline Centre (UK). Ablation:Atrial fibrillation:diagnosis and management:Network meta-analysis J2[M]. London:National Institute for Health and Care Excellence (NICE),2021.
[36] Otto CM,Nishimura RA,Bonow RO,et al. 2020 ACC/AHA Guideline for the Management of Patients with Valvular Heart Disease:Executive Summary:a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. J Am Coll Cardiol,2021,143(5):e35-e71.
[37] Baumgartner H,Falk V,Bax JJ,et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease[J]. Eur Heart J,2017,38(36):2739-2791.
[38] Williams AM,Brescia AA,Watt TMF,et al.Transcatheter therapy for tricuspid regurgitation:the surgical perspective[J]. Prog Cardiovasc Dis,2019,62(6):473-478.
[39] Darby AE. Pulsed field ablation:a novel therapeutic tool for catheter-based treatment of atrial fibrillation[J]. Curr Cardiol Rep,2022,24(7):793-799.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(8):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(8):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(8):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(8):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(8):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(8):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(8):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(8):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(8):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(8):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]